Recent studies have revealed evidences that tumor cells may adaptively upregulate their expression of PD-L1 after treatment with anti-PD-1 antibodies, representing a mechanism of acquired resistance to ICB immunotherapy17,18. Here, CD274 is linked to neoplasm.